The CJC-1295 + Ipamorelin blend combines a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone-releasing peptide (GHRP) for growth hormone axis research. This combination has been studied for synergistic stimulation of pulsatile GH secretion with minimal effects on cortisol or prolactin.
This blend combines two mechanistically distinct stimulators of growth hormone (GH) release that act at different points in the hypothalamic-pituitary axis. CJC-1295 (no DAC), also known as Modified GRF(1-29) or Mod-GRF, is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It binds to the GHRH receptor on anterior pituitary somatotroph cells, activating adenylyl cyclase and raising intracellular cAMP levels. This stimulates GH gene transcription and pulsatile GH secretion. The modified amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, extending the biological half-life.
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Unlike earlier GHRPs (such as GHRP-6 or GHRP-2), ipamorelin shows high selectivity for GH release with minimal stimulation of ACTH, cortisol, or prolactin at physiological doses. This selectivity makes it a preferred research tool for studying isolated GH axis effects.
When combined, these compounds produce a synergistic GH response: CJC-1295 provides the GHRH signal that 'primes' the somatotroph, while ipamorelin's ghrelin-mimetic activity amplifies the GH pulse. This mirrors the physiological interplay between GHRH and ghrelin in endogenous GH regulation. Preclinical and early clinical research suggests the combination produces larger and more sustained GH pulses than either compound alone.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R. · Journal of Clinical Endocrinology and Metabolism (2006)
Clinical study demonstrating sustained GH and IGF-1 elevation following CJC-1295 (with DAC) administration in healthy subjects, with effects lasting up to 6 days.
DOI: 10.1210/jc.2005-1528Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology (1998)
Characterisation of ipamorelin as the first truly selective GH secretagogue, with potent GH release and minimal effects on ACTH, cortisol, and prolactin in preclinical models.
DOI: 10.1530/eje.0.1390552Growth hormone-releasing peptide (GHRP)
Bowers CY. · Cellular and Molecular Life Sciences (1998)
Comprehensive review of GHRP pharmacology, establishing the framework for understanding ghrelin-receptor-mediated GH secretion and the synergy between GHRH and GHRP signalling.
DOI: 10.1007/s000180050349Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. · Journal of Clinical Endocrinology and Metabolism (2006)
Demonstrated that CJC-1295 preserves the pulsatile pattern of GH secretion rather than causing continuous elevation, supporting its use in physiological GH axis research.
DOI: 10.1210/jc.2006-1toyBoth peptides are co-lyophilised. Add bacteriostatic water slowly along the vial wall and allow complete dissolution. Do not shake or vortex. For research protocols, note that the blend ratio is pre-determined and cannot be independently adjusted.
Use reconstitution calculatorLyophilised: store at or below 5 °C for up to 12 months. Reconstituted: refrigerate at 2–8 °C and use within 30 days. GH secretagogues are generally stable in solution but should be protected from heat and light.
CJC-1295 with DAC (Drug Affinity Complex) has a maleimido-derivative that binds to albumin, extending the half-life to days. CJC-1295 without DAC (also called Mod-GRF 1-29) has a shorter half-life of approximately 30 minutes. The no-DAC form is used in this blend for more precise, pulsatile GH release research.
Ipamorelin is the first selective GH secretagogue, producing potent GH release with minimal stimulation of ACTH, cortisol, or prolactin. Earlier GHRPs like GHRP-6 and GHRP-2 stimulate these secondary hormones, making them less specific as GH axis research tools.
CJC-1295 activates the GHRH receptor (priming the somatotroph cell) while ipamorelin activates the ghrelin receptor (GHS-R1a), amplifying the GH pulse. This mirrors the physiological cooperation between GHRH and ghrelin in natural pulsatile GH secretion.
For research and laboratory purposes only. Not for human use. These statements have not been evaluated by the Therapeutic Goods Administration (TGA). This product is not intended to diagnose, treat, cure, or prevent any disease.
